Clin Ther 2005, 27: 588–593.CrossRefPubMed
8. Yang HW, Xie YQ, Guo QL: Clinical observation of propofol combined with flurbiprofen axetil for induced abortion anesthesia. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2006, 31: 752–755.PubMed 9. Ou Yang X, Wang W, Peng Y, et al.: Analgesic effect of flurbiprofen axetil injection on cancer pain. Chinese Journal of Pain Medicine 2005, 11: 281–283. 10. Wong DL, Baker CM: Pain in children: comparison of assessment scales. Pediatr Nurs 1988, 14: 9–17.PubMed 11. World Health Organization: Cancer pain relief and palliative care. Geneva: World Health Organization 1990. 12. NCI: Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events. [http://ctep.cancer.gov] Version 3.0 2003. 13. Mizushima Y, Shoji Y, Kato T, Fukushima M, Kurozumi S: Use of lipid microspheres as a drug carrier for antitumour drugs. J Pharm Pharmacol 1986, 38: 132–134.PubMed 14. Washinton C: Stability Selleck BI 10773 of lipid emulsions for drug deliver. Adv Drug Delivery Rev 1996, 20: 131–145.CrossRef 15. Park KM, AG-881 Lee MK, Hwang KJ, Kim CK: Phospholipid-based microemulsions of flurbiprofen by the spontaneous emulsification process. Int J Pharm 1999, 183: 145–154.CrossRefPubMed 16. Yamazaki Y, Sonoda H, Seki S: Effects of preoperatively administered flurbiprofen axetil
on the action of inhaled anesthesia and postoperative pain. Masui 1995, 44: 1238–1241.PubMed 17. Xu G, Li X, Duan L, Zhu T, Xie Q, Zhou Y, Wang B, Deng Y, Shen L, Yuan X: Phase II clinical study for flubiprofen axetil injection in treatment of moderate postoperative pain. Chinese New Drugs Journal 2004, 13: 846–848. 18. Duan L, Li X: Clinical application these of flurbiprofen axetil injection. Chinese New Drugs Journal 2004, 13: 851–852. Competing interests The authors declare
that they have no competing interests. Authors’ contributions HW collected the data and drafted the manuscript, ZC designed this study and modified the manuscript, GS, KG, YP, JH, YD, JN participated in its design and coordination. All authors read and approved the final manuscript.”
“Background Prostate cancer is the most common cancer among men in industrialized countries with the main risk factor being the age of over 50. Prostate cancer is uncommon in men younger than 45, but becomes more common with increasing age. The average age at the time of diagnosis is 65 [1–4]. Since early detection increases the chance of successful treatment, the prostate-specific antigen (PSA) test and the digital rectal examination should be offered to men annually beginning at age 50. Men with high risk should begin testing at age 45. The only well-established risk factors for prostate cancer are age, ethnicity, geography and family history of prostate cancer. However, research in the past few years has shown that genetic, socioeconomic and environmental factors, particularly diet and lifestyle, likely have an effect as well.